Funding for the IBD/FBD Review Group (September 1, 2010 to August 31, 2015) was provided by the Canadian Institutes of Health Research (CIHR) Knowledge Translation Branch (CON- 105529) and the CIHR Institutes of Nutrition, Metabolism and Diabetes (INMD); and Infection and Immunity (III) and the Ontario Ministry of Health and Long Term Care (HLTC3968FL- 2010-2235). Miss Ila Stewart provided support for the IBD/FBD Review Group through the Olive Stewart Fund.
Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis†
Article first published online: 29 MAY 2012
Copyright © 2012 Crohn's & Colitis Foundation of America, Inc.
Inflammatory Bowel Diseases
Volume 18, Issue 9, pages 1785–1794, September 2012
How to Cite
Feagan, B. G. and MacDonald, J. K. (2012), Once daily oral mesalamine compared to conventional dosing for induction and maintenance of remission in ulcerative colitis: A systematic review and meta-analysis. Inflamm Bowel Dis, 18: 1785–1794. doi: 10.1002/ibd.23024
- Issue published online: 9 AUG 2012
- Article first published online: 29 MAY 2012
- Manuscript Accepted: 30 APR 2012
- Manuscript Received: 20 APR 2012